Remove Adverse Reactions Remove Immunity Remove Immunization
article thumbnail

Herd immunity is nice – but what about me?

pharmaphorum

Shahrokh Shabahang discusses why we need a personalised approach to COVID-19 immunity testing. While these numbers do tell us something about the relative immunity of the population writ large, they don’t tell us anything about our own, personal immune profiles. What does that mean in real-world terms?

Immunity 105
article thumbnail

Non-vaccine nasal spray could protect against COVID-19

pharmaphorum

That could be important if it takes longer than expected to bring vaccines and antibodies to market, said a spokesman for the companies, pointing to the news this week that AstraZeneca has halted phase 3 trials of its COVID-19 vaccine candidate AZD1222 after a serious adverse reaction in one patient.

Vaccines 133
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Mix and match regimen of AZ and Pfizer COVID jabs works well

pharmaphorum

Giving one dose each of AstraZeneca and Pfizer COVID-19 vaccines provides good protection against the SARS-CoV-2 virus, but may be associated with more adverse reactions, according to new clinical trial data. “There is an excellent response to a second dose, even after a 10 month delay from the first.”

Vaccines 128
article thumbnail

EC approves Libtayo® for metastatic cervical cancer

European Pharmaceutical Review

Immune-mediated adverse reactions (ARs) occurred in 21 percent of patients treated with Libtayo ® and led to permanent discontinuation in 4.6 The most common immune-mediated ARs were hypothyroidism (6.8 percent), hyperthyroidism (3 percent), immune-mediated pneumonitis (2.6 percent), immune-mediated hepatitis (2.4

article thumbnail

Moderna’s Covid-19/influenza vaccine phase III data highlights potential of mRNA technology for infectious diseases: GlobalData

Express Pharma

The investigational combination mRNA vaccine generated statistically significant higher immune responses in relation to the licensed comparator vaccines used in the randomised, observer-blind, active control study among 8,000 adults aged 50 years and older.

Vaccines 104
article thumbnail

FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel

pharmaphorum

The most common adverse reactions seen in a trial cohort of 38,000 patients were at injection sites (84.1%) followed by fatigue (62.9%) and headache (55.1%), and serious adverse reactions occurred in 0% to 4.6% of participants.

Vaccines 111
article thumbnail

US FDA approves Apellis’ geographic atrophy therapy Syfovre

Pharmaceutical Technology

It provides comprehensive control of the complement cascade, which is part of the immune system of the body, by targeting C3. Vitreous floaters, ocular discomfort, conjunctival hemorrhage, and neovascular AMD were the most common adverse reactions observed in patients receiving Syfovre.